RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Everest Medicines, a Shanghai in-licensing company, has appointed Kerry Blanchard, MD, PhD, as CEO. Dr. Blanchard is a long-term China biopharma executive with ten years of experience leading China drug development programs at Lilly and Innovent. His hiring illustrates that Everest remains committed to its China-centric business plan, despite the recent COVID-19 disruption. In a statement, Dr. Blanchard said, “China’s importance to global pharmaceutical development continues to rise and I will work with the Board to explore strategic opportunities outside of our traditional focus of licensing regional rights to late-stage programs.”
Source: China Biotoday
